Neuraminidase Inhibitors in Influenza Treatment and Prevention⁻Is It Time to Call It a Day?
Identifieur interne : 000259 ( PubMed/Checkpoint ); précédent : 000258; suivant : 000260Neuraminidase Inhibitors in Influenza Treatment and Prevention⁻Is It Time to Call It a Day?
Auteurs : César Parra-Rojas [Allemagne] ; Van Kinh Nguyen [Allemagne] ; Gustavo Hernandez-Mejia [Allemagne] ; Esteban A. Hernandez-Vargas [Allemagne]Source :
- Viruses [ 1999-4915 ] ; 2018.
Descripteurs français
- KwdFr :
- Algorithmes, Antienzymes (administration et posologie), Antienzymes (pharmacologie), Antienzymes (usage thérapeutique), Antiviraux (administration et posologie), Antiviraux (usage thérapeutique), Grippe humaine (), Grippe humaine (traitement médicamenteux), Grippe humaine (épidémiologie), Humains, Logiciel, Modèles théoriques, Oséltamivir (administration et posologie), Oséltamivir (usage thérapeutique), Sialidase (antagonistes et inhibiteurs), Virus de la grippe A (), Virus de la grippe A (enzymologie), Épidémies ().
- MESH :
- administration et posologie : Antienzymes, Antiviraux, Oséltamivir.
- antagonistes et inhibiteurs : Sialidase.
- enzymologie : Virus de la grippe A.
- pharmacologie : Antienzymes.
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Antienzymes, Antiviraux, Oséltamivir.
- épidémiologie : Grippe humaine.
- Algorithmes, Grippe humaine, Humains, Logiciel, Modèles théoriques, Virus de la grippe A, Épidémies.
English descriptors
- KwdEn :
- Algorithms, Antiviral Agents (administration & dosage), Antiviral Agents (therapeutic use), Enzyme Inhibitors (administration & dosage), Enzyme Inhibitors (pharmacology), Enzyme Inhibitors (therapeutic use), Epidemics (prevention & control), Humans, Influenza A virus (drug effects), Influenza A virus (enzymology), Influenza, Human (drug therapy), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Models, Theoretical, Neuraminidase (antagonists & inhibitors), Oseltamivir (administration & dosage), Oseltamivir (therapeutic use), Software.
- MESH :
- chemical , administration & dosage : Antiviral Agents, Enzyme Inhibitors, Oseltamivir.
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , pharmacology : Enzyme Inhibitors.
- chemical , therapeutic use : Antiviral Agents, Enzyme Inhibitors, Oseltamivir.
- drug effects : Influenza A virus.
- drug therapy : Influenza, Human.
- enzymology : Influenza A virus.
- epidemiology : Influenza, Human.
- prevention & control : Epidemics, Influenza, Human.
- Algorithms, Humans, Models, Theoretical, Software.
Abstract
Stockpiling neuraminidase inhibitors (NAIs) such as oseltamivir and zanamivir is part of a global effort to be prepared for an influenza pandemic. However, the contribution of NAIs for the treatment and prevention of influenza and its complications is largely debatable due to constraints in the ability to control for confounders and to explore unobserved areas of the drug effects. For this study, we used a mathematical model of influenza infection which allowed transparent analyses. The model recreated the oseltamivir effects and indicated that: (i) the efficacy was limited by design, (ii) a 99% efficacy could be achieved by using high drug doses (however, taking high doses of drug 48 h post-infection could only yield a maximum of 1.6-day reduction in the time to symptom alleviation), and (iii) contributions of oseltamivir to epidemic control could be high, but were observed only in fragile settings. In a typical influenza infection, NAIs' efficacy is inherently not high, and even if their efficacy is improved, the effect can be negligible in practice.
DOI: 10.3390/v10090454
PubMed: 30149615
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:30149615Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuraminidase Inhibitors in Influenza Treatment and Prevention⁻Is It Time to Call It a Day?</title><author><name sortKey="Parra Rojas, Cesar" sort="Parra Rojas, Cesar" uniqKey="Parra Rojas C" first="César" last="Parra-Rojas">César Parra-Rojas</name><affiliation wicri:level="1"><nlm:affiliation>Frankfurt Institute for Advanced Studies, 60438 Frankfurt am Main, Hessen, Germany. cesar.parra.r@gmail.com.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Frankfurt Institute for Advanced Studies, 60438 Frankfurt am Main, Hessen</wicri:regionArea><wicri:noRegion>Hessen</wicri:noRegion><wicri:noRegion>Hessen</wicri:noRegion><wicri:noRegion>Hessen</wicri:noRegion></affiliation></author><author><name sortKey="Nguyen, Van Kinh" sort="Nguyen, Van Kinh" uniqKey="Nguyen V" first="Van Kinh" last="Nguyen">Van Kinh Nguyen</name><affiliation wicri:level="1"><nlm:affiliation>Frankfurt Institute for Advanced Studies, 60438 Frankfurt am Main, Hessen, Germany. admin@ytecongcong.com.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Frankfurt Institute for Advanced Studies, 60438 Frankfurt am Main, Hessen</wicri:regionArea><wicri:noRegion>Hessen</wicri:noRegion><wicri:noRegion>Hessen</wicri:noRegion><wicri:noRegion>Hessen</wicri:noRegion></affiliation></author><author><name sortKey="Hernandez Mejia, Gustavo" sort="Hernandez Mejia, Gustavo" uniqKey="Hernandez Mejia G" first="Gustavo" last="Hernandez-Mejia">Gustavo Hernandez-Mejia</name><affiliation wicri:level="1"><nlm:affiliation>Frankfurt Institute for Advanced Studies, 60438 Frankfurt am Main, Hessen, Germany. gustavohdezm@gmail.com.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Frankfurt Institute for Advanced Studies, 60438 Frankfurt am Main, Hessen</wicri:regionArea><wicri:noRegion>Hessen</wicri:noRegion><wicri:noRegion>Hessen</wicri:noRegion><wicri:noRegion>Hessen</wicri:noRegion></affiliation></author><author><name sortKey="Hernandez Vargas, Esteban A" sort="Hernandez Vargas, Esteban A" uniqKey="Hernandez Vargas E" first="Esteban A" last="Hernandez-Vargas">Esteban A. Hernandez-Vargas</name><affiliation wicri:level="1"><nlm:affiliation>Frankfurt Institute for Advanced Studies, 60438 Frankfurt am Main, Hessen, Germany. vargas@fias.uni-frankfurt.de.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Frankfurt Institute for Advanced Studies, 60438 Frankfurt am Main, Hessen</wicri:regionArea><wicri:noRegion>Hessen</wicri:noRegion><wicri:noRegion>Hessen</wicri:noRegion><wicri:noRegion>Hessen</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:30149615</idno><idno type="pmid">30149615</idno><idno type="doi">10.3390/v10090454</idno><idno type="wicri:Area/PubMed/Corpus">000252</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000252</idno><idno type="wicri:Area/PubMed/Curation">000252</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000252</idno><idno type="wicri:Area/PubMed/Checkpoint">000259</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000259</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Neuraminidase Inhibitors in Influenza Treatment and Prevention⁻Is It Time to Call It a Day?</title><author><name sortKey="Parra Rojas, Cesar" sort="Parra Rojas, Cesar" uniqKey="Parra Rojas C" first="César" last="Parra-Rojas">César Parra-Rojas</name><affiliation wicri:level="1"><nlm:affiliation>Frankfurt Institute for Advanced Studies, 60438 Frankfurt am Main, Hessen, Germany. cesar.parra.r@gmail.com.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Frankfurt Institute for Advanced Studies, 60438 Frankfurt am Main, Hessen</wicri:regionArea><wicri:noRegion>Hessen</wicri:noRegion><wicri:noRegion>Hessen</wicri:noRegion><wicri:noRegion>Hessen</wicri:noRegion></affiliation></author><author><name sortKey="Nguyen, Van Kinh" sort="Nguyen, Van Kinh" uniqKey="Nguyen V" first="Van Kinh" last="Nguyen">Van Kinh Nguyen</name><affiliation wicri:level="1"><nlm:affiliation>Frankfurt Institute for Advanced Studies, 60438 Frankfurt am Main, Hessen, Germany. admin@ytecongcong.com.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Frankfurt Institute for Advanced Studies, 60438 Frankfurt am Main, Hessen</wicri:regionArea><wicri:noRegion>Hessen</wicri:noRegion><wicri:noRegion>Hessen</wicri:noRegion><wicri:noRegion>Hessen</wicri:noRegion></affiliation></author><author><name sortKey="Hernandez Mejia, Gustavo" sort="Hernandez Mejia, Gustavo" uniqKey="Hernandez Mejia G" first="Gustavo" last="Hernandez-Mejia">Gustavo Hernandez-Mejia</name><affiliation wicri:level="1"><nlm:affiliation>Frankfurt Institute for Advanced Studies, 60438 Frankfurt am Main, Hessen, Germany. gustavohdezm@gmail.com.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Frankfurt Institute for Advanced Studies, 60438 Frankfurt am Main, Hessen</wicri:regionArea><wicri:noRegion>Hessen</wicri:noRegion><wicri:noRegion>Hessen</wicri:noRegion><wicri:noRegion>Hessen</wicri:noRegion></affiliation></author><author><name sortKey="Hernandez Vargas, Esteban A" sort="Hernandez Vargas, Esteban A" uniqKey="Hernandez Vargas E" first="Esteban A" last="Hernandez-Vargas">Esteban A. Hernandez-Vargas</name><affiliation wicri:level="1"><nlm:affiliation>Frankfurt Institute for Advanced Studies, 60438 Frankfurt am Main, Hessen, Germany. vargas@fias.uni-frankfurt.de.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Frankfurt Institute for Advanced Studies, 60438 Frankfurt am Main, Hessen</wicri:regionArea><wicri:noRegion>Hessen</wicri:noRegion><wicri:noRegion>Hessen</wicri:noRegion><wicri:noRegion>Hessen</wicri:noRegion></affiliation></author></analytic><series><title level="j">Viruses</title><idno type="eISSN">1999-4915</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Algorithms</term><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (therapeutic use)</term><term>Enzyme Inhibitors (administration & dosage)</term><term>Enzyme Inhibitors (pharmacology)</term><term>Enzyme Inhibitors (therapeutic use)</term><term>Epidemics (prevention & control)</term><term>Humans</term><term>Influenza A virus (drug effects)</term><term>Influenza A virus (enzymology)</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Models, Theoretical</term><term>Neuraminidase (antagonists & inhibitors)</term><term>Oseltamivir (administration & dosage)</term><term>Oseltamivir (therapeutic use)</term><term>Software</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Algorithmes</term><term>Antienzymes (administration et posologie)</term><term>Antienzymes (pharmacologie)</term><term>Antienzymes (usage thérapeutique)</term><term>Antiviraux (administration et posologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Grippe humaine ()</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Logiciel</term><term>Modèles théoriques</term><term>Oséltamivir (administration et posologie)</term><term>Oséltamivir (usage thérapeutique)</term><term>Sialidase (antagonistes et inhibiteurs)</term><term>Virus de la grippe A ()</term><term>Virus de la grippe A (enzymologie)</term><term>Épidémies ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term><term>Enzyme Inhibitors</term><term>Oseltamivir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Enzyme Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Enzyme Inhibitors</term><term>Oseltamivir</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antienzymes</term><term>Antiviraux</term><term>Oséltamivir</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Influenza A virus</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antienzymes</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Epidemics</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antienzymes</term><term>Antiviraux</term><term>Oséltamivir</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Algorithms</term><term>Humans</term><term>Models, Theoretical</term><term>Software</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Algorithmes</term><term>Grippe humaine</term><term>Humains</term><term>Logiciel</term><term>Modèles théoriques</term><term>Virus de la grippe A</term><term>Épidémies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Stockpiling neuraminidase inhibitors (NAIs) such as oseltamivir and zanamivir is part of a global effort to be prepared for an influenza pandemic. However, the contribution of NAIs for the treatment and prevention of influenza and its complications is largely debatable due to constraints in the ability to control for confounders and to explore unobserved areas of the drug effects. For this study, we used a mathematical model of influenza infection which allowed transparent analyses. The model recreated the oseltamivir effects and indicated that: (i) the efficacy was limited by design, (ii) a 99% efficacy could be achieved by using high drug doses (however, taking high doses of drug 48 h post-infection could only yield a maximum of 1.6-day reduction in the time to symptom alleviation), and (iii) contributions of oseltamivir to epidemic control could be high, but were observed only in fragile settings. In a typical influenza infection, NAIs' efficacy is inherently not high, and even if their efficacy is improved, the effect can be negligible in practice.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30149615</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>9</Issue><PubDate><Year>2018</Year><Month>08</Month><Day>25</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Neuraminidase Inhibitors in Influenza Treatment and Prevention⁻Is It Time to Call It a Day?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">E454</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v10090454</ELocationID><Abstract><AbstractText>Stockpiling neuraminidase inhibitors (NAIs) such as oseltamivir and zanamivir is part of a global effort to be prepared for an influenza pandemic. However, the contribution of NAIs for the treatment and prevention of influenza and its complications is largely debatable due to constraints in the ability to control for confounders and to explore unobserved areas of the drug effects. For this study, we used a mathematical model of influenza infection which allowed transparent analyses. The model recreated the oseltamivir effects and indicated that: (i) the efficacy was limited by design, (ii) a 99% efficacy could be achieved by using high drug doses (however, taking high doses of drug 48 h post-infection could only yield a maximum of 1.6-day reduction in the time to symptom alleviation), and (iii) contributions of oseltamivir to epidemic control could be high, but were observed only in fragile settings. In a typical influenza infection, NAIs' efficacy is inherently not high, and even if their efficacy is improved, the effect can be negligible in practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parra-Rojas</LastName><ForeName>César</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3625-9412</Identifier><AffiliationInfo><Affiliation>Frankfurt Institute for Advanced Studies, 60438 Frankfurt am Main, Hessen, Germany. cesar.parra.r@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Van Kinh</ForeName><Initials>VK</Initials><Identifier Source="ORCID">0000-0001-8912-5288</Identifier><AffiliationInfo><Affiliation>Frankfurt Institute for Advanced Studies, 60438 Frankfurt am Main, Hessen, Germany. admin@ytecongcong.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernandez-Mejia</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Frankfurt Institute for Advanced Studies, 60438 Frankfurt am Main, Hessen, Germany. gustavohdezm@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernandez-Vargas</LastName><ForeName>Esteban A</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0002-3645-435X</Identifier><AffiliationInfo><Affiliation>Frankfurt Institute for Advanced Studies, 60438 Frankfurt am Main, Hessen, Germany. vargas@fias.uni-frankfurt.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058872" MajorTopicYN="N">Epidemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008962" MajorTopicYN="N">Models, Theoretical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="N">Software</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">epidemics</Keyword><Keyword MajorTopicYN="Y">influenza</Keyword><Keyword MajorTopicYN="Y">mathematical modeling</Keyword><Keyword MajorTopicYN="Y">neuraminidase inhibitor</Keyword><Keyword MajorTopicYN="Y">oseltamivir</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>07</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>08</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>08</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30149615</ArticleId><ArticleId IdType="pii">v10090454</ArticleId><ArticleId IdType="doi">10.3390/v10090454</ArticleId><ArticleId IdType="pmc">PMC6163920</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Drugs. 2001;61(2):263-83</Citation><ArticleIdList><ArticleId IdType="pubmed">11270942</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2006 Apr 21;312(5772):382-3</Citation><ArticleIdList><ArticleId IdType="pubmed">16627733</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Comput Biol. 2014 Apr 17;10(4):e1003568</Citation><ArticleIdList><ArticleId IdType="pubmed">24743564</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull World Health Organ. 2012 Oct 1;90(10):782-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23109746</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 1999 Mar-Apr;61(2):175-80</Citation><ArticleIdList><ArticleId IdType="pubmed">10204970</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2015 May 2;385(9979):1729-1737</Citation><ArticleIdList><ArticleId IdType="pubmed">25640810</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Public Health. 2014 Sep 29;14:1019</Citation><ArticleIdList><ArticleId IdType="pubmed">25266818</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2005 Sep 29;353(13):1363-73</Citation><ArticleIdList><ArticleId IdType="pubmed">16192481</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2015 Oct 12;7(10):5274-304</Citation><ArticleIdList><ArticleId IdType="pubmed">26473911</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2005 Jan 27;352(4):405-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15668221</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2014 Apr 10;348:g2263</Citation><ArticleIdList><ArticleId IdType="pubmed">24721793</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2016 Jun;22(6):949-55</Citation><ArticleIdList><ArticleId IdType="pubmed">27191818</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2017 Nov 1;72(11):2990-3007</Citation><ArticleIdList><ArticleId IdType="pubmed">28961794</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Pharmacol. 2008 Aug;48(8):935-47</Citation><ArticleIdList><ArticleId IdType="pubmed">18524996</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2014 Apr 10;(4):CD008965</Citation><ArticleIdList><ArticleId IdType="pubmed">24718923</ArticleId></ArticleIdList></Reference><Reference><Citation>J Intensive Care Med. 2017 Dec;32(10):574-577</Citation><ArticleIdList><ArticleId IdType="pubmed">26992784</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1:7-13</Citation><ArticleIdList><ArticleId IdType="pubmed">23279892</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2008 Mar 25;5(3):e74</Citation><ArticleIdList><ArticleId IdType="pubmed">18366252</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2013 May 30;346:f3039</Citation><ArticleIdList><ArticleId IdType="pubmed">23723457</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2000 Mar 4;355(9206):827-35</Citation><ArticleIdList><ArticleId IdType="pubmed">10711940</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2015 May 2;385(9979):1700-1702</Citation><ArticleIdList><ArticleId IdType="pubmed">25640811</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Drug Resist. 2013 Nov 19;6:187-98</Citation><ArticleIdList><ArticleId IdType="pubmed">24277988</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2007 Jan;4(1):e15</Citation><ArticleIdList><ArticleId IdType="pubmed">17253900</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2009 Mar;53(3):945-52</Citation><ArticleIdList><ArticleId IdType="pubmed">19104028</ArticleId></ArticleIdList></Reference><Reference><Citation>Math Biosci. 2010 May;225(1):24-35</Citation><ArticleIdList><ArticleId IdType="pubmed">20102724</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2010 Apr;65 Suppl 2:ii5-ii10</Citation><ArticleIdList><ArticleId IdType="pubmed">20215135</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country></list><tree><country name="Allemagne"><noRegion><name sortKey="Parra Rojas, Cesar" sort="Parra Rojas, Cesar" uniqKey="Parra Rojas C" first="César" last="Parra-Rojas">César Parra-Rojas</name></noRegion><name sortKey="Hernandez Mejia, Gustavo" sort="Hernandez Mejia, Gustavo" uniqKey="Hernandez Mejia G" first="Gustavo" last="Hernandez-Mejia">Gustavo Hernandez-Mejia</name><name sortKey="Hernandez Vargas, Esteban A" sort="Hernandez Vargas, Esteban A" uniqKey="Hernandez Vargas E" first="Esteban A" last="Hernandez-Vargas">Esteban A. Hernandez-Vargas</name><name sortKey="Nguyen, Van Kinh" sort="Nguyen, Van Kinh" uniqKey="Nguyen V" first="Van Kinh" last="Nguyen">Van Kinh Nguyen</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000259 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000259 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:30149615
|texte= Neuraminidase Inhibitors in Influenza Treatment and Prevention⁻Is It Time to Call It a Day?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:30149615" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |